Catalyst Pharmaceuticals(CPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CPRX Catalyst Pharmaceuticals

Not Yet Opened 06-16 16:00:00 EDT

31.35

-0.02

-0.06%

盘后31.38

+0.03+0.10%

19:46 EDT

High31.38	Low31.34	Vol1.84M
Open31.37	D1 Closing31.37	Amplitude0.13%
Mkt Cap3.83B	Tradable Cap3.61B	Total Shares122.12M
T/O57.63M	T/O Rate1.60%	Tradable Shares115.02M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CPRX","market":"US","secType":"STK","nameCN":"Catalyst Pharmaceuticals","latestPrice":31.35,"timestamp":1781640000000,"preClose":31.37,"halted":0,"volume":1837524,"hourTrading":{"tag":"盘后","latestPrice":31.38,"preClose":31.35,"latestTime":"19:46 EDT","volume":98069,"amount":3074980.5853,"timestamp":1781653618056,"change":0.03,"changeRate":0.000957,"amplitude":0.000957},"delay":0,"changeRate":-0.0006375518010838245,"floatShares":115016976,"shares":122123884,"eps":1.729853,"marketStatus":"Not Yet Opened","change":-0.02,"latestTime":"06-16 16:00:00 EDT","open":31.37,"high":31.38,"low":31.34,"amount":57631375.076496,"amplitude":0.001275,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.729853,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1781683200000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1162962000000,"exchange":"NASDAQ","adjPreClose":31.37,"preHourTrading":{"tag":"盘前","latestPrice":31.36,"preClose":31.37,"latestTime":"09:29 EDT","volume":1253,"amount":39291.530145,"timestamp":1781616598039,"change":-0.01,"changeRate":-0.000319,"amplitude":0.001594},"postHourTrading":{"tag":"盘后","latestPrice":31.38,"preClose":31.35,"latestTime":"19:46 EDT","volume":98069,"amount":3074980.5853,"timestamp":1781653618056,"change":0.03,"changeRate":0.000957,"amplitude":0.000957},"volumeRatio":1.316919,"impliedVol":0.1739,"impliedVolPercentile":0.108},"requestUrl":"/m/hq/s/CPRX/tweets","defaultTab":"tweets","newsList":[{"id":"2642572432","title":"Catalyst Pharmaceuticals Sets July 2026 Vote on $31.50-per-Share Angelini Pharma Buyout","url":"https://stock-news.laohu8.com/highlight/detail?id=2642572432","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642572432?lang=en_us&edition=fundamental","pubTime":"2026-06-09 05:27","pubTimestamp":1780954043,"startTime":"0","endTime":"0","summary":"New activity is brewing for Catalyst Pharma ( ($CPRX) ). The company has submitted a Form DEFM14A to the SEC, indicating an upcoming shareholder vo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/catalyst-pharmaceuticals-sets-july-2026-vote-on-31-50-per-share-angelini-pharma-buyout?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/catalyst-pharmaceuticals-sets-july-2026-vote-on-31-50-per-share-angelini-pharma-buyout?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B19Z6F94.USD","CPRX","BK4139","IE0034390439.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639697775","title":"Catalyst Pharmaceuticals Cut to Neutral From Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2639697775","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639697775?lang=en_us&edition=fundamental","pubTime":"2026-05-29 00:53","pubTimestamp":1779987180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CPRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 28, 2026 12:53 ET (16:53 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639852690","title":"Catalyst Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2639852690","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639852690?lang=en_us&edition=fundamental","pubTime":"2026-05-29 00:51","pubTimestamp":1779987064,"startTime":"0","endTime":"0","summary":"H.C. Wainwright downgraded Catalyst Pharmaceuticals (CPRX) to Neutral from Buy with a $31.50 price target after the company agreed to be acquired b...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/catalyst-pharmaceuticals-downgraded-to-neutral-from-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/catalyst-pharmaceuticals-downgraded-to-neutral-from-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637398133","title":"CVC, GBL launch €10.7 billion bid for Italian drugmaker Recordati","url":"https://stock-news.laohu8.com/highlight/detail?id=2637398133","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637398133?lang=en_us&edition=fundamental","pubTime":"2026-05-22 13:38","pubTimestamp":1779428320,"startTime":"0","endTime":"0","summary":"UPDATE 3-CVC, GBL launch 10.7 billion bid for Italian drugmaker RecordatiCVC first invested in Recordati in 2018Italy's pharmaceutical sector in the midst of dealmakingCVCGBL bid aims to unlock value through further deals Updates with further offer details and analyst comments from paragraph 9 onwardsBy Elvira Pollina and Giulia Segreti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nL8N41Z08G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KALV","CPRX","IE00B19Z6F94.USD","IE0034390439.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636092959","title":"Angelini Buyout And Firdapse Settlement Reframe Catalyst Pharmaceuticals Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2636092959","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636092959?lang=en_us&edition=fundamental","pubTime":"2026-05-17 17:39","pubTimestamp":1779010789,"startTime":"0","endTime":"0","summary":"Catalyst Pharmaceuticals, ticker NasdaqCM:CPRX, has agreed to be acquired by Angelini Pharma in a definitive all cash transaction.\nThe company has settled all pending Firdapse patent litigation, granting generic licenses that run through 2035.\nThe deal marks an exit for current public shareholders and is set to reshape how Catalyst Pharmaceuticals operates within the rare disease drug market.\n\nCatalyst Pharmaceuticals focuses on treatments for rare neurological conditions, with Firdapse as a...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/angelini-buyout-and-firdapse-settlement-reframe-catalyst-pha","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/angelini-buyout-and-firdapse-settlement-reframe-catalyst-pha","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE0034390439.USD","IE00B19Z6F94.USD","BK4139","CPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634259191","title":"Catalyst Pharmaceuticals reports Q1 non-GAAP EPS 79c, consensus 64c","url":"https://stock-news.laohu8.com/highlight/detail?id=2634259191","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634259191?lang=en_us&edition=fundamental","pubTime":"2026-05-12 07:59","pubTimestamp":1778543999,"startTime":"0","endTime":"0","summary":"Reports Q1 revenue $149.4M, consensus $148.18M. FIRDAPSE Q1 2026 product revenue, net was $98.9 million, an 18.1% year-over-year increase, primaril...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/catalyst-pharmaceuticals-reports-q1-non-gaap-eps-79c-consensus-64c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/catalyst-pharmaceuticals-reports-q1-non-gaap-eps-79c-consensus-64c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634259468","title":"Catalyst Pharmaceuticals not providing forward-looking guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2634259468","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634259468?lang=en_us&edition=fundamental","pubTime":"2026-05-12 07:57","pubTimestamp":1778543823,"startTime":"0","endTime":"0","summary":"In light of the Company’s May 7, 2026 announcement, Catalyst will not be providing forward-looking guidance or updates to previously issued guidanc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/catalyst-pharmaceuticals-not-providing-forward-looking-guidance-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/catalyst-pharmaceuticals-not-providing-forward-looking-guidance-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0034390439.USD","IE00B19Z6F94.USD","BK4139","CPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634581042","title":"Catalyst Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2634581042","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634581042?lang=en_us&edition=fundamental","pubTime":"2026-05-12 05:00","pubTimestamp":1778533249,"startTime":"0","endTime":"0","summary":"Catalyst Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings SummaryCatalyst Pharmaceuticals Inc CPRX.OQ reported quarterly adjusted earnings of 50 cents per share for the qu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL8N41O2KB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CPRX","IE00B19Z6F94.USD","IE0034390439.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634560230","title":"Catalyst Pharmaceuticals' Q1 revenue slightly beats estimates on increased prescriber engagement","url":"https://stock-news.laohu8.com/highlight/detail?id=2634560230","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634560230?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:29","pubTimestamp":1778531380,"startTime":"0","endTime":"0","summary":"Catalyst Pharmaceuticals' Q1 revenue slightly beats estimates on increased prescriber engagementOverviewU.S. biopharmaceutical firm's Q1 revenue rose 5.6% yr/yr, slightly beating analyst expectationsA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL1N41O10M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE0034390439.USD","CPRX","IE00B19Z6F94.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634237068","title":"Catalyst Q1 2026 GAAP net income rises 12.3% to $63.7 million; revenue climbs 5.6% to $149.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634237068","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634237068?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:24","pubTimestamp":1778531047,"startTime":"0","endTime":"0","summary":"Catalyst Pharmaceuticals posted Q1 2026 revenue of $149.4 million, up 5.6% year over year.GAAP net income rose 12.3% to $63.7 million, with diluted EPS of $0.5.Operating income climbed 15.6% to $73.2 million as cost of sales fell to $14.5 million from lower FIRDAPSE royalties.FIRDAPSE revenue increased 18.1% to $98.9 million, AGAMREE revenue jumped 66.6% to $36.7 million, while FYCOMPA revenue dropped 61.3% to $13.8 million following loss of exclusivity in 2025.Cash and cash equivalents increased 6.6% to $755.9 million; Catalyst reiterated it will not provide forward-looking guidance or host an earnings call.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL7mj4hP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4139","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","IE00BKPKM429.USD","NDAQ","SG9999014039.USD","LU2210150020.SGD","LU2095319765.USD","LU0314104364.USD","CPRX","SG9999014013.SGD","IE00BN0W2T93.GBP","BK4585","SG9999014021.USD","LU2210149790.SGD","IE0034390439.USD","BK4588","IE00BN0W2W23.USD","BK4112","SG9999014005.SGD","IE00B19Z6F94.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634723754","title":"BRIEF-Catalyst Pharmaceuticals Q1 Revenue USD 149.4 Million Vs. IBES Estimate USD 148.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634723754","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634723754?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:13","pubTimestamp":1778530410,"startTime":"0","endTime":"0","summary":"BRIEF-Catalyst Pharmaceuticals Q1 Revenue USD 149.4 Million Vs. IBES Estimate USD 148.2 Million\n\n\nMay 11 (Reuters) - Catalyst Pharmaceuticals Q1 operating income USD 73.2 million.\n\nQ1 net income USD 63.7 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nPLX546D74:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0034390439.USD","BK4139","IE00B19Z6F94.USD","CPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634375182","title":"Catalyst Pharmaceuticals Q1 Sales $149.390M Beat $148.174M Estimate.","url":"https://stock-news.laohu8.com/highlight/detail?id=2634375182","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634375182?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:12","pubTimestamp":1778530362,"startTime":"0","endTime":"0","summary":"Catalyst Pharmaceuticals (NASDAQ:CPRX) reported quarterly sales of $149.390 million which beat the analyst consensus estimate of $148.174 million by 0.82 percent.  This is a 5.63 percent increase over sales of $141.421","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52468677/catalyst-pharmaceuticals-q1-sales-149-390m-beat-148-174m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Catalyst Pharmaceuticals Q1 Sales $149.390M Beat $148.174M Estimate.","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634237086","title":"Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2634237086","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634237086?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:12","pubTimestamp":1778530320,"startTime":"0","endTime":"0","summary":"Delivered Q1 2026 Total Revenuesof$149.4 MillionResults include 28% YoY Increase in Net Product Revenues from FIRDAPSE & AGAMREE Reported Cash and Cash Equivalents of $755.9 Million and No Funded Debt","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/11/3292348/13009/en/Catalyst-Pharmaceuticals-Reports-First-Quarter-2026-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CPRX","IE00B19Z6F94.USD","IE0034390439.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634840099","title":"Catalyst Pharmaceuticals Inc : Citigroup Cuts to Neutral From Buy; Cuts Target Price to $31.50 From $35","url":"https://stock-news.laohu8.com/highlight/detail?id=2634840099","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634840099?lang=en_us&edition=fundamental","pubTime":"2026-05-11 18:33","pubTimestamp":1778495589,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nFWN41O0VD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CPRX","IE00B19Z6F94.USD","IE0034390439.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634403112","title":"U.S. RESEARCH ROUNDUP-Airbnb, HII, Tesla","url":"https://stock-news.laohu8.com/highlight/detail?id=2634403112","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634403112?lang=en_us&edition=fundamental","pubTime":"2026-05-11 15:27","pubTimestamp":1778484476,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Airbnb, HII, Tesla May 11 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Airbnb, HII and Tesla, o","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL4N41O0GT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBU","BWXT","CAR","CWH","BAM","BBIO","AGL","WHD","ASTH","AVB","CTRI","ALB","ABNY","BILL","AMDL","F","ABNB","AMUU","AZTA","ARTV","ANIP","AMYY","AMPH","AIZ","AFRM","CF","BWA","APO","CRI","AMD","TECH","ALBG","AIDX","ASPN","BP","ARXS","BDX","BOOT","CG","AFRU","CPRX","AMDW","BCAX","ATLC","CRC","FRDU","ABNG","AMDD","CPT","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634416499","title":"Catalyst FIRDAPSE Deal Extends Exclusivity To 2035 And Shapes Angelini Bid","url":"https://stock-news.laohu8.com/highlight/detail?id=2634416499","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634416499?lang=en_us&edition=fundamental","pubTime":"2026-05-09 22:36","pubTimestamp":1778337416,"startTime":"0","endTime":"0","summary":"Catalyst Pharmaceuticals (NasdaqCM:CPRX) has settled all pending FIRDAPSE patent litigation with Hetero Labs.\nThe agreement prevents Hetero from launching a generic FIRDAPSE product in the U.S. before January 2035.\nThe settlement secures extended U.S. market exclusivity for FIRDAPSE and removes a key legal overhang for Catalyst.\n\nCatalyst Pharmaceuticals focuses on treatments for rare neurological diseases, with FIRDAPSE as its lead commercial product. In that context, the settlement with...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/catalyst-firdapse-deal-extends-exclusivity-to-2035-and-shape","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/catalyst-firdapse-deal-extends-exclusivity-to-2035-and-shape","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CPRX","BK4139","IE00B19Z6F94.USD","IE0034390439.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634607914","title":"Catalyst Pharmaceuticals downgraded to Neutral from Buy at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2634607914","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634607914?lang=en_us&edition=fundamental","pubTime":"2026-05-09 06:11","pubTimestamp":1778278308,"startTime":"0","endTime":"0","summary":"Citi downgraded Catalyst Pharmaceuticals (CPRX) to Neutral from Buy with a $31.50 price target after Angelini Pharma announced it will acquire Cata...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/catalyst-pharmaceuticals-downgraded-to-neutral-from-buy-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/catalyst-pharmaceuticals-downgraded-to-neutral-from-buy-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634615284","title":"Catalyst Pharmaceuticals Cut to Neutral From Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2634615284","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634615284?lang=en_us&edition=fundamental","pubTime":"2026-05-09 03:17","pubTimestamp":1778267820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CPRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 08, 2026 15:17 ET (19:17 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633170218","title":"Catalyst Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2633170218","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633170218?lang=en_us&edition=fundamental","pubTime":"2026-05-08 05:22","pubTimestamp":1778188920,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Catalyst Pharmaceuticals Inc.  rallied 2.11% to $31.17 Thursday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite Index  falling 0.13% to 25,806.20 and Dow Jones Industrial Average  falling 0.63% to 49,596.97.Catalyst Pharmaceuticals Inc. closed 4.28% short of its 52-week high of $32.56, which the company achieved on April 27th.The stock outperformed some of its competitors Thursday, as Johnson & Johnson  fell 0.94% to $222.51, Pfizer Inc.  fell 0.19% to $26.48, and Abbott Laboratories  rose 0.82% to $87.01.Trading volume  eclipsed its 50-day average volume of 1.5 M.Data source: Dow Jones Market Data, FactSet. Data compiled May 7, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFXG1179.USD","BK4139","LU2237957811.SGD","LU1244550577.SGD","LU1721429402.USD","BK4588","LU1883839398.USD","LU1551013342.USD","IE00B19Z3B42.SGD","LU1718418525.SGD","LU1929549753.HKD","LU0689626769.HKD","BK4568","LU1057294990.SGD","BK4533","LU0053666078.USD","LU0683600562.USD","LU1121112475.USD","LU1989763427.SGD","SG9999002224.SGD","LU0994945656.USD","IE00BJJMRZ35.SGD","SGXZ23171101.USD","LU0320765646.SGD","IE000SO60NU8.SGD","LU2602419157.SGD","LU0795875169.SGD","LU1989763690.USD","LU2129689605.HKD","LU0234570918.USD","SG9999002232.USD","LU1585245621.USD","SG9999001176.USD","IE00BKVL7J92.USD","LU1023059063.AUD","IE0002270589.USD","BK4532","IE00BBT3K403.USD","LU0689472784.USD","LU1691799644.USD","LU2089984988.USD","BK4585","LU2471134796.USD","LU0820561818.USD","SG9999001440.SGD","LU2417539215.USD","LU0345769631.USD","BK4559","IE00BJT1NW94.SGD","LU1043141123.HKD","LU0426417589.USD","LU0795875086.SGD","LU1145028129.USD","LU0210536198.USD","IE00BDGV0183.EUR","IE00B1BXHZ80.USD","LU1061106388.HKD","LU0114720955.EUR","IE0009355771.USD","IE0000B7K699.USD","IE00B2B36J28.USD","IE00B42XCP33.USD","LU0820562030.AUD","LU1228905037.USD","LU1914381329.SGD","LU2403377893.USD","IE000WAW04H5.SGD","LU0868494617.USD","LU0345770308.USD","LU1506573853.SGD","LU1778281490.HKD","LU0985481810.HKD","LU0456855351.SGD","LU1221951129.SGD","LU0234572021.USD","LU1032466523.USD","LU2750360641.GBP","LU0345770993.USD","IE0001KFT4U8.USD","LU2750360997.AUD","IE00BVYPNV92.GBP","LU2471134879.HKD","LU2430703178.SGD","IE0034390439.USD","LU1074936037.SGD","LU0098860793.USD","LU0321505439.SGD","LU0985320562.USD","CPRX","IE00B7SZLL34.SGD","LU2430703251.USD","BK4082","IE00B19Z3581.USD","LU0289739699.SGD","LU0466842654.USD","LU1935042991.SGD","BK4534","SG9999011175.SGD","LU1043141396.HKD","LU0266013472.USD","IE0034235303.USD","IE00BGHQF631.EUR","LU1674673428.USD","IE000F7OJYX1.SGD","LU0787776722.HKD","LU1032955483.USD","LU1732800096.USD","LU1496350502.SGD","LU0058720904.USD","LU1267930813.SGD","LU1066051811.HKD","LU1066053197.SGD","LU2487616109.SGD","BK4592","SG9999003800.SGD","LU1228905540.USD","LU2236285917.USD","LU1551013425.SGD","SG9999001176.SGD","LU2505996681.GBP","IE00BVYPNW00.USD","LU1162221912.USD","LU2468319806.SGD","LU1280957306.USD","LU2347655156.SGD","LU1066051498.USD","LU2456880835.USD","SG9999013999.USD","LU0225284248.USD","LU2471134952.CNY","LU1244550494.USD","LU2211815571.USD","BK4550","LU2129689431.USD","LU0964807845.USD","BK4566","LU2237957902.USD","LU0345769128.USD","IE00B3T34201.USD","LU1732799900.SGD","LU0882574055.USD","SG9999004303.SGD","LU1244550221.USD","LU1674673691.USD","LU2023250330.USD","IE000M9KFDE8.USD","LU0912757837.SGD","BK4504","LU0426412945.USD","LU0070217475.USD","LU0792757196.USD","LU1059921491.USD","IE00BZ1G4Q59.USD","LU0122379950.USD","LU2324357040.USD","LU2430703095.HKD","LU1629891620.HKD","LU2896262040.SGD","LU1066051225.USD","LU0203347892.USD","SGXZ41872573.SGD","LU1983299246.USD","LU1721429741.USD","LU2756315664.SGD","BK4581","LU0943347566.SGD","LU0225771236.USD","LU0124676726.USD","LU0432979614.USD","LU2112291526.USD","IE00BLSP4452.SGD","LU0306807586.USD","LU0210528500.USD","IE00BSNM7G36.USD","LU0820561909.HKD","LU2756315318.SGD","IE000BZT7R73.USD","LU2129689514.USD","LU0889566641.SGD","IE0002141913.USD","LU0545562505.USD","LU1261432733.SGD","LU1196500208.SGD","BK4599","LU0321505868.SGD","LU0306806265.USD","LU2133065610.SGD","IE00B3PB1722.GBP","LU0170899867.USD","BK4007","IE00BLSP4239.USD","LU2471134523.USD","LU1894683348.USD","LU0640476718.USD","LU2213496289.HKD","LU2505996509.AUD","SGXZ57979304.SGD","IE00B4R5TH58.HKD","LU1430594728.SGD","IE00BFTCPJ56.SGD","IE00BN8TJ469.HKD","IE000MB6IJN5.SGD","LU2592432038.USD","IE00B19Z6F94.USD","LU1221951046.USD","LU1894683264.USD","LU0203345920.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633176191","title":"Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2633176191","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633176191?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:02","pubTimestamp":1778184120,"startTime":"0","endTime":"0","summary":"Melissa Kendis, Catalyst Pharmaceuticals, Inc.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3290519/13009/en/Catalyst-Pharmaceuticals-Cancels-First-Quarter-2026-Conference-Call-and-Webcast.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CPRX","IE00B19Z6F94.USD","IE0034390439.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.catalystpharma.com","stockEarnings":[{"period":"1week","weight":0.0003},{"period":"1month","weight":0.0055},{"period":"3month","weight":0.3744},{"period":"6month","weight":0.3245},{"period":"1year","weight":0.3245},{"period":"ytd","weight":0.3432}],"compareEarnings":[{"period":"1week","weight":0.018},{"period":"1month","weight":0.0151},{"period":"3month","weight":0.1344},{"period":"6month","weight":0.1092},{"period":"1year","weight":0.245},{"period":"ytd","weight":0.1003}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.054585},{"month":2,"riseRate":0.65,"avgChangeRate":-0.012753},{"month":3,"riseRate":0.7,"avgChangeRate":0.100484},{"month":4,"riseRate":0.45,"avgChangeRate":0.039847},{"month":5,"riseRate":0.6,"avgChangeRate":-0.02255},{"month":6,"riseRate":0.55,"avgChangeRate":0.036646},{"month":7,"riseRate":0.578947,"avgChangeRate":0.111528},{"month":8,"riseRate":0.631579,"avgChangeRate":0.2208},{"month":9,"riseRate":0.368421,"avgChangeRate":-0.027783},{"month":10,"riseRate":0.473684,"avgChangeRate":-0.048724},{"month":11,"riseRate":0.578947,"avgChangeRate":0.015249},{"month":12,"riseRate":0.3,"avgChangeRate":-0.029987}],"exchange":"NASDAQ","name":"Catalyst Pharmaceuticals","nameEN":"Catalyst Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Catalyst Pharmaceuticals(CPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Catalyst Pharmaceuticals(CPRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Catalyst Pharmaceuticals,CPRX,Catalyst Pharmaceuticals股票,Catalyst Pharmaceuticals股票老虎,Catalyst Pharmaceuticals股票老虎国际,Catalyst Pharmaceuticals行情,Catalyst Pharmaceuticals股票行情,Catalyst Pharmaceuticals股价,Catalyst Pharmaceuticals股市,Catalyst Pharmaceuticals股票价格,Catalyst Pharmaceuticals股票交易,Catalyst Pharmaceuticals股票购买,Catalyst Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Catalyst Pharmaceuticals(CPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Catalyst Pharmaceuticals(CPRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}